Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study

Wonseok Lee; Sunghoon Lee; Hyoung Won Bae; Chan Yun Kim; Gong Je Seong

doi:10.1186/s12886-017-0453-z

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study

Wonseok Lee, Sunghoon Lee, Hyoung Won Bae, Chan Yun Kim, Gong Je Seong

Department of Ophthalmology

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.

Original language	English
Article number	61
Journal	BMC Ophthalmology
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s12886-017-0453-z
Publication status	Published - 2017 Apr 28

Bibliographical note

Funding Information:
No financial support or funding was received in this study. None of all authors have any financial or property interest on any product, method or material presented in this paper. No conflicting relationship exists for any author. The authors have no conflict of interest to declare.

Publisher Copyright:
© 2017 The Author(s).

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1186/s12886-017-0453-z

Cite this

@article{269ec148bd5a450a94c6fd8fe21bf89c,

title = "Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study",

abstract = "Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.",

author = "Wonseok Lee and Sunghoon Lee and Bae, {Hyoung Won} and Kim, {Chan Yun} and Seong, {Gong Je}",

note = "Funding Information: No financial support or funding was received in this study. None of all authors have any financial or property interest on any product, method or material presented in this paper. No conflicting relationship exists for any author. The authors have no conflict of interest to declare. Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = apr,

day = "28",

doi = "10.1186/s12886-017-0453-z",

language = "English",

volume = "17",

journal = "BMC Ophthalmology",

issn = "1471-2415",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients

T2 - a prospective crossover study

AU - Lee, Wonseok

AU - Lee, Sunghoon

AU - Bae, Hyoung Won

AU - Kim, Chan Yun

AU - Seong, Gong Je

N1 - Funding Information: No financial support or funding was received in this study. None of all authors have any financial or property interest on any product, method or material presented in this paper. No conflicting relationship exists for any author. The authors have no conflict of interest to declare. Publisher Copyright: © 2017 The Author(s).

PY - 2017/4/28

Y1 - 2017/4/28

N2 - Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.

AB - Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.

UR - http://www.scopus.com/inward/record.url?scp=85018170441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018170441&partnerID=8YFLogxK

U2 - 10.1186/s12886-017-0453-z

DO - 10.1186/s12886-017-0453-z

M3 - Article

C2 - 28454526

AN - SCOPUS:85018170441

VL - 17

JO - BMC Ophthalmology

JF - BMC Ophthalmology

SN - 1471-2415

IS - 1

M1 - 61

ER -

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this